The GNRH1 Knockout T-47D Polyclonal Cells product comprises a population of T-47D human breast ductal carcinoma cells that have undergone CRISPR/Cas9-mediated disruption of the gonadotropin-releasing hormone 1 (GNRH1) gene. This polyclonal pool represents a heterogeneous mixture of edited cells, providing a versatile loss-of-function model for studying the autocrine and paracrine roles of GnRH in breast cancer biology. The knockout cell population is generated without single-cell cloning, ensuring retention of diverse genetic backgrounds that may mitigate clonal artifacts. The product is supplied as a ready-to-use cryopreserved vial, suitable for immediate expansion and downstream functional analyses. Researchers can employ this tool to interrogate the contribution of GNRH1 to signaling networks and cellular phenotypes in an estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) mammary epithelial context.
Derived from the pleural effusion of a 54-year-old female with infiltrating ductal carcinoma, the T-47D host cell line is a well-characterized model of luminal A breast cancer. These cells express high levels of estrogen and progesterone receptors, rendering them responsive to hormonal stimuli and widely used for investigating endocrine therapy mechanisms. T-47D cells maintain epithelial morphology and recapitulate key features of hormone-dependent breast tumors, including the ability to form xenografts in immunocompromised mice. Their receptor status and origin from a metastatic site make them particularly relevant for studying tumor progression and hormone resistance. This background provides a clinically pertinent milieu in which to dissect the functions of neuroendocrine factors such as GnRH that may modulate cancer cell behavior beyond classical endocrine paradigms.
The GNRH1 gene encodes a decapeptide hormone best known for its hypothalamic role in regulating pituitary gonadotropin secretion. At the molecular level, GnRH binds to its cognate receptor GNRHR, a Gq/11-coupled seven-transmembrane receptor, activating phospholipase C (PLC) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG). These second messengers mobilize intracellular calcium and activate protein kinase C (PKC), which in turn stimulates the MAPK cascade, including ERK1/2 (MAPK1/3), JNK, and p38. Downstream targets of this cascade include transcription factors such as c-Fos and c-Jun, as well as regulators of apoptosis like Bcl-2 and Bax. In extrapituitary tissues, GnRH signaling is influenced by upstream modulators including kisspeptin (KISS1), sex steroids, and neurokinin B, and can exert antiproliferative and proapoptotic effects through phosphotyrosine phosphatase activation and cross-talk with growth factor pathways. The GNRH1 knockout disrupts this entire signaling axis, enabling dissection of ligand-dependent versus receptor-autonomous functions.
In T-47D breast cancer cells, endogenous GnRH expression forms an autocrine/paracrine loop that may restrain cell proliferation and promote apoptosis, potentially counteracting estrogen-driven growth. Disruption of GNRH1 in this ER+/PR+ model allows investigation of how the loss of GnRH signaling alters sensitivity to hormonal therapies such as tamoxifen or aromatase inhibitors. The polyclonal knockout population provides a realistic representation of the heterogeneous responses that might occur in tumor microenvironments. By comparing parental and knockout cells, researchers can elucidate the interplay between GnRH and estrogen receptor pathways, including the modulation of MAPK activity and transcriptional programs that drive cell cycle progression or death. This model is particularly valuable for exploring mechanisms of resistance to endocrine treatments, where GnRH signaling may be rewired.
This knockout product supports a wide range of experimental applications. Typical assays include western blotting and RT?qPCR to confirm disruption of GNRH1 and assess downstream targets such as LHB, FSHB, or Bcl-2 family members. Cell proliferation (MTS, BrdU) and apoptosis (Annexin V, caspase-3) assays quantify functional consequences of GnRH loss. Migration and invasion studies, GnRH ELISA, and reporter gene workflows further characterize the phenotype. Phospho-ERK analysis and RNA-seq provide insights into altered signaling networks, while drug sensitivity screens evaluate responses to hormonal agents. These applications position the GNRH1 Knockout T-47D Polyclonal Cells as a robust resource for breast cancer signal transduction research. For detailed product information, please contact Ascent Research.
